Stay updated on Avelumab/Axitinib vs Sunitinib in Advanced Renal Cell Cancer Clinical Trial

Sign up to get notified when there's something new on the Avelumab/Axitinib vs Sunitinib in Advanced Renal Cell Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Avelumab/Axitinib vs Sunitinib in Advanced Renal Cell Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents an update in the phase 3 study evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy in patients with advanced renal cell carcinoma.
    Difference
    0.0%
    Check dated 2024-06-06T14:58:54.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the health conditions and prior treatments required for inclusion in the study. Previously, this section indicated that no information was provided.
    Difference
    11%
    Check dated 2024-05-22T21:28:55.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T22:47:07.000Z thumbnail image

Stay in the know with updates to Avelumab/Axitinib vs Sunitinib in Advanced Renal Cell Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Avelumab/Axitinib vs Sunitinib in Advanced Renal Cell Cancer Clinical Trial page.